NTV Asset Management LLC purchased a new stake in VanEck Pharmaceutical ETF (NASDAQ:PPH – Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,033 shares of the company’s stock, valued at approximately $661,000. NTV Asset Management LLC owned about 0.06% of VanEck Pharmaceutical ETF at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of VanEck Pharmaceutical ETF by 846.9% during the first quarter. Royal Bank of Canada now owns 361,001 shares of the company’s stock worth $37,501,000 after acquiring an additional 322,878 shares during the last quarter. Adamsbrown Wealth Consultants LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 3.6% in the second quarter. Adamsbrown Wealth Consultants LLC now owns 154,114 shares of the company’s stock worth $16,852,000 after acquiring an additional 5,303 shares during the period. Bank of America Corp DE lifted its stake in shares of VanEck Pharmaceutical ETF by 139.3% in the first quarter. Bank of America Corp DE now owns 143,609 shares of the company’s stock worth $14,918,000 after acquiring an additional 83,598 shares during the period. Rye Brook Capital LLC lifted its stake in shares of VanEck Pharmaceutical ETF by 4.3% in the third quarter. Rye Brook Capital LLC now owns 70,255 shares of the company’s stock worth $7,691,000 after acquiring an additional 2,925 shares during the period. Finally, Fluent Financial LLC bought a new stake in VanEck Pharmaceutical ETF in the second quarter valued at approximately $4,264,000.
VanEck Pharmaceutical ETF Price Performance
Shares of PPH stock opened at $114.93 on Monday. The business’s 50 day simple moving average is $112.41 and its 200 day simple moving average is $108.22. VanEck Pharmaceutical ETF has a one year low of $90.74 and a one year high of $118.03. The stock has a market capitalization of $1.07 billion, a PE ratio of 20.21 and a beta of 0.45.
VanEck Pharmaceutical ETF Cuts Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, October 6th. Shareholders of record on Thursday, October 1st were issued a dividend of $0.36 per share. This represents a $1.44 annualized dividend and a yield of 1.3%. The ex-dividend date was Thursday, October 1st. This is a negative change from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.6248.
VanEck Pharmaceutical ETF Profile
The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.
Featured Articles
- Five stocks we like better than VanEck Pharmaceutical ETF
- Newmont’s Record Quarter Shows Why Gold’s Floor Is the Real Story
- Albemarle Upgrade: Can Energy Storage Recharge Lithium’s Leader?
- Consumer Staples Are Up 12% This Year—These 3 Beverage Stocks Are Leading the Way
- Can Planet Fitness Get Its Growth Back in Shape?
Receive News & Ratings for VanEck Pharmaceutical ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VanEck Pharmaceutical ETF and related companies with MarketBeat.com's FREE daily email newsletter.
